• Users Online: 175
  • Print this page
  • Email this page

Table of Contents
Year : 2020  |  Volume : 3  |  Issue : 1  |  Page : 45

Introducing the 3rd Annual PARP and DNA Damage Response Inhibitors Summit

Date of Web Publication21-Feb-2020

Correspondence Address:
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/2666-2345.277794

Get Permissions

How to cite this article:
. Introducing the 3rd Annual PARP and DNA Damage Response Inhibitors Summit. J Immunother Precis Oncol 2020;3:45

How to cite this URL:
. Introducing the 3rd Annual PARP and DNA Damage Response Inhibitors Summit. J Immunother Precis Oncol [serial online] 2020 [cited 2020 Apr 2];3:45. Available from: http://www.jipoonline.org/text.asp?2020/3/1/45/277794

The Journal of Immunotherapy and Precision Oncology (JIPO) is proud to support this event and encourages readers to attend in Boston, MA on January 28-30, 2020.

As the field continues to evolve at an accelerated rate, it is important for the industry to gather and discuss their challenges and share their solutions. Industry-focused meetings such as the PARP and DDR Inhibitors Summit (Jan 28-30, 2020 in Boston, MA, previously “DNA Damage Response Therapeutics Summit”) are key events to meet the stars of your DDR news feeds! The 3-day event is designed to equip researchers and drug developers with the tools for blockbuster therapy success and the connections to effectively advance their work.

The meeting boasts 20 plenary sessions, 25 expert speakers and 2 open panel discussions. Experts from Cybrexa Therapeutics, Cyteir and Ribon Therapeutics will be there to run analysis of 7 novel DDR targets in addition to 2 exclusive deep-dive workshops. Attendees will take advantage of more than 5 hours of networking with 80+ leaders in the space. The major challenges and successes for DDR researchers will be addressed by the Heads, Chiefs, and Presidents of discovery, translation, and clinical practice from Pharma Biotech and Academia.

An Exclusive Interview With Jipo Editor and Speaker, Dr. Timothy Yap

Dr. Timothy Yap is a Medical Oncologist and Physician-Scientist based at the University of Texas MD Anderson Cancer Center.

Dr. Yap's main research focuses on the first-in-human and combinatorial development of molecularly targeted agents and immunotherapies, and their acceleration through clinical studies using novel predictive and pharmacodynamic biomarkers.

What, in your opinion, are the 3 greatest challenges faced in the DDR therapy field today?

  • Determining the specific mechanisms that underlie response and resistance to DDR therapies
  • Establishing registration strategies for DDR therapies beyond PARP inhibitors, e.g. ATR, DNA-PK, ATM, WEE1 inhibitors.
  • Managing challenging overlapping toxicities observed with DDR combination therapies, e.g. myelosuppression.

How do you envision these challenges being addressed? What interesting progress being made to further the field?

  • Translational studies undertaken on sequential tumor biopsies and ctDNA samples taken from patients on DDR therapies will provide greater insights into specific mechanisms that underlie response and resistance to DDR therapies
  • Innovative early phase clinical trials that assess the respective roles of DDR therapies beyond PARP inhibitors are being undertaken with early promise being made.
  • Innovative strategies, such as the creative scheduling of DDR combination therapies, as well as the use of drug conjugates with alphalex peptides to enable a more tumor-specific delivery of DDR agents are showing promise preclinically, and are novel approaches about to enter the clinic soon.

What are the most important or promising DDR targets in your opinion and why?

The most important DDR targets are PARP, ATR, ATM, DNA-PK, WEE1, CHK1/2 and POLQ, as these are potentially druggable targets for the clinic.

Where do you see DDR therapy fitting in the universe of cancer therapy? ie combination approaches, maintenance therapy, which line of therapy, precision medicine…

I see DDR therapy as a platform therapy with multiple applications, as monotherapy using molecularly-driven approaches, as seen with BRCA1/2 mutant cancers, both in the maintenance and relapse settings, in differrernt lines of therapy, and also in combination approaches to deepen responses, reverse resistance and increase the proportion of patients who may respond to single agent strategies.


The interview was first published in the PARP and DDP Summit Library and reprinted with permission.

The PARP and DDR Inhibitors Summit is a Hanson Wade event and will be held in Boston, MA, on January 28-30, 2020. To learn more about collaboration and partnerships with industry leaders through this open platform, please visit: www.parp-ddr-inhibitors-summit.com or contact info@hansonwade.com.

The PARP & DDR community is supported by Patrys, Genomic Vision & Ambry Genetics.


Media Enquiries: Ariane Jacobs | E: info@hansonwade.com

Commercial Enquiries: Nicholas Ramovic | Tel: +1 617 455 4188 | E: sponsor@hansonwade.com


    Similar in PUBMED
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article
   An Exclusive Int...

 Article Access Statistics
    PDF Downloaded16    
    Comments [Add]    

Recommend this journal